Mostrando 2 resultados de: 2
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusSuperior efficacy and safety of a nonemulsive variant of the NGcGM3/VSSP vaccine in advanced breast cancer patients
ArticleAbstract: NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vacPalabras claves:Breast Cancer, NGcGM3/VSSP vaccine, SurvivalAutores:Arencibia M., Cabrera L., Carmen Elena Viada, Cepeda M., De La Torre A.V., Domecq M., Durán Y., Durrutí D., Fernandez L.E., Hernández J.J., Hernández L., Mabel Álvarez, Moreno Y.G., Pérez K., Ruiz R., Sánchez J.L., Sánchez L., Santiesteban E.R., Valls A.R., Vega A.M.Fuentes:scopus